Claim

A decentralized longevity study that uses an AMM-style dynamic reward curve-in which token compensation rises for biosamples contributed by statistically underrepresented biomarker-response states-will identify responder subgroups more efficiently than a flat-pay incentive design.

Mechanistic rationale

Most tokenized research designs pay equally for every data point. That is good for volume, but bad for information density. In aging biology, the most valuable observations are often rare: extreme epigenetic-age deceleration, unusually strong CRP suppression, paradoxical LDL responses to fasting, non-responders to exercise, or transient glucose-instability signatures after senolytic or dietary interventions.

A DeFi-style reward curve can price scarcity directly. Analogous to an AMM increasing price when liquidity is scarce, a trial smart contract can increase payout weight when a participant's newly submitted biomarker trajectory falls into a sparsely sampled region of response space. The financial mechanism should change participant behavior: higher-value follow-up sampling is concentrated precisely where biological heterogeneity is most informative.

Biologically, that should improve detection of response phenotypes rather than just average treatment effects. Instead of merely asking whether an intervention shifts the mean, the study becomes better at mapping which metabolic, inflammatory, or epigenetic baselines predict benefit versus harm.

Testable predictions

1. Compared with flat compensation, the dynamic-curve arm will produce lower entropy loss in the tails of biomarker distributions and at least 25% more complete follow-up among rare responder classes.
2. Clustering analysis on longitudinal biomarkers (for example DNAm age, hs-CRP, fasting insulin, ApoB, HRV, CGM-derived glucose variability) will recover more stable responder subtypes in the dynamic-curve arm.
3. Predictive models trained on the dynamic-curve dataset will show better out-of-sample classification of responders/non-responders than models trained on an equally sized flat-pay dataset.
4. The advantage will be strongest in interventions with known heterogeneity, such as time-restricted feeding, structured exercise, rapamycin analogues, or microbiome-directed nutrition.

Experimental design

Run the same decentralized 9-12 month longevity protocol under two payment rules:

• Flat-pay control: fixed token payout per completed data submission.
• Dynamic AMM-style arm: payout multiplier increases as a participant's biomarker state becomes rarer in the live dataset, subject to caps to prevent gaming.

Primary endpoints:

• completeness of follow-up within rare biomarker-response strata,
• subtype stability under repeated clustering / bootstrap resampling,
• predictive accuracy for response classification,
• and administrative fraud rate.

Falsification

The hypothesis fails if the dynamic reward curve does not improve rare-state sampling, does not improve subtype discovery, or induces enough gaming / adverse selection that the information gain disappears.

Why it matters

If true, DeFi incentive design is not only a funding wrapper for DeSci. It becomes an experimental measurement tool for aging biology: a way to spend rewards where marginal biological information is highest.